Preoperative platelet aggregation testing is a specialized laboratory assay that evaluates the functional capacity of platelets, complementing routine coagulation screens such as prothrombin time (PT) and activated partial thromboplastin time (aPTT) before surgery. Because abnormal platelet function is one of the leading causes of unexpected perioperative bleeding, this test plays a critical role in preoperative risk stratification, antiplatelet therapy management, and transfusion planning. This article provides a comprehensive technical overview of preoperative platelet aggregation testing, including sample requirements, testing items, analytical methods, clinical applications, and frequently asked questions.
Technical Overview
Platelet aggregation testing measures the ability of platelets to aggregate in response to specific agonists, providing a functional assessment that cannot be obtained from platelet counting or standard coagulation parameters alone. During the assay, a platelet agonist is introduced to a blood sample, and the resulting aggregation response is quantified photometrically or electrochemically. The magnitude, velocity, and pattern of the aggregation curve reflect the integrity of platelet receptors, signaling pathways, and granule secretion.
In the preoperative setting, platelet aggregation testing is indicated for patients with a history of unexplained bleeding or bruising, individuals taking antiplatelet medications such as aspirin or P2Y12 inhibitors, patients with suspected inherited platelet function disorders, and candidates for high bleeding-risk procedures such as cardiac surgery with cardiopulmonary bypass, neurosurgery, or ophthalmic surgery. Testing is typically performed in accordance with recognized laboratory standards, including CLSI guidelines for platelet function testing, and laboratories conducting these assays are expected to operate under quality management systems compliant with ISO 15189 for medical laboratory accreditation.
It is important to distinguish platelet aggregation testing from routine coagulation tests: PT and aPTT evaluate the coagulation factor cascade, whereas platelet aggregation assays evaluate primary hemostasis. A patient may have a normal coagulation screen and normal platelet count yet still exhibit significant platelet dysfunction detectable only through functional testing.
Testing Samples
Citrated Platelet-Rich Plasma (PRP)
For light transmission aggregometry, venous blood is collected into 3.2% sodium citrate tubes at a 9:1 blood-to-anticoagulant ratio. Platelet-rich plasma is prepared by low-speed centrifugation (approximately 150–200 g for 10 minutes), while platelet-poor plasma is obtained by further high-speed centrifugation and used as the optical blank. The platelet count of PRP should ideally be adjusted to a standardized range, typically 200–300 × 10⁹/L, to ensure comparability of results.
Whole Blood for Impedance Aggregometry
Whole blood impedance (multi-electrode) aggregometry uses blood anticoagulated with hirudin, which preserves physiological divalent cation concentrations and platelet responsiveness. This approach requires no sample preparation, is less sensitive to thrombocytopenia and lipemia, and is well suited to point-of-care or near-patient testing in perioperative environments.
Sample Collection and Handling Requirements
- Collect samples atraumatically using a large-bore needle; discard the first few milliliters to avoid tissue factor activation.
- Avoid difficult venipuncture, prolonged tourniquet application, hemolysis, and clotted specimens.
- Maintain samples at room temperature (20–25 °C); do not refrigerate, as chilling can activate or damage platelets.
- Testing should be completed promptly, generally within 2–4 hours of collection for PRP-based methods and within approximately 30 minutes to 3 hours for whole blood methods, depending on the analytical system.
- Patients should avoid high-fat meals before sampling; where clinically permissible, platelet-active medications (aspirin, NSAIDs, P2Y12 inhibitors, dipyridamole, and certain antibiotics and antidepressants) should be documented or withheld for 7–14 days prior to diagnostic testing to avoid pharmacological interference.
Testing Items
A standard preoperative platelet aggregation panel evaluates aggregation responses to a panel of agonists, each probing a distinct receptor or activation pathway:
- ADP-induced aggregation: Assesses P2Y1/P2Y12 receptor pathways; commonly used to monitor clopidogrel and other P2Y12 inhibitor effects.
- Arachidonic acid-induced aggregation: Evaluates the cyclooxygenase-1/thromboxane A2 pathway; highly sensitive to aspirin effect.
- Collagen-induced aggregation: Tests glycoprotein VI/Ia-mediated activation and granule secretion.
- Epinephrine-induced aggregation: Probes alpha-adrenergic platelet receptors as part of a comprehensive panel.
- Ristocetin-induced platelet agglutination: Assesses glycoprotein Ib-IX-V interaction with von Willebrand factor; essential for screening von Willebrand disease and Bernard-Soulier syndrome.
- TRAP (thrombin receptor-activating peptide)-induced aggregation: Evaluates PAR-1 mediated activation, useful as an internal control for platelet responsiveness independent of aspirin and P2Y12 pathways.
Reported parameters typically include maximum aggregation percentage, aggregation slope (rate), lag phase, and the presence or absence of a second-wave aggregation response. Interpretive patterns are diagnostic signatures; for example, uniformly reduced aggregation to all agonists except normal ristocetin response suggests Glanzmann thrombasthenia, whereas isolated impairment of ristocetin-induced agglutination suggests von Willebrand disease or Bernard-Soulier syndrome.
Testing Methods
Light Transmission Aggregometry (LTA)
Light transmission aggregometry, historically known as the Born method, is the reference technique for platelet function testing. Platelet-rich plasma is stirred at 37 °C in a cuvette, an agonist is added, and platelet aggregation increases light transmission relative to the platelet-poor plasma blank. The resulting aggregation curve is recorded photometrically. LTA offers high sensitivity and a broad agonist panel but demands meticulous sample preparation, standardized PRP platelet counts, and rapid testing, and it is generally performed in specialized hemostasis laboratories of accredited third-party laboratories or hospital reference centers.
Whole Blood Impedance Aggregometry
Impedance-based methods measure the increase in electrical resistance between electrodes as activated platelets adhere and aggregate onto the electrode surface in anticoagulated whole blood. The technique requires minimal sample manipulation, uses near-physiological conditions, and delivers results within approximately 5–10 minutes, making it well suited for perioperative and point-of-care antiplatelet effect monitoring.
Quality Control and Standardization
- Verify agonist potency, concentration, and expiration; run parallel normal donor controls with each batch.
- Follow CLSI guidance on platelet function testing and maintain method-specific reference intervals validated for the local population.
- Participate in external quality assessment programs and maintain ISO 15189-compliant documentation of preanalytical, analytical, and postanalytical processes.
- Document all medications with antiplatelet activity taken within the preceding 10–14 days, as these are the most common cause of reduced aggregation responses.
Applications
- Preoperative bleeding risk stratification: Identifying patients with impaired platelet function before cardiac surgery with cardiopulmonary bypass, neurosurgery, spinal surgery, ophthalmic surgery, ENT procedures, and other interventions where even minor bleeding carries serious consequences.
- Antiplatelet therapy management: Assessing residual antiplatelet drug effect before urgent or elective surgery, guiding decisions on surgical timing, drug interruption intervals, bridging strategies, and perioperative platelet transfusion requirements.
- Diagnosis of inherited platelet function disorders: Characterizing conditions such as Glanzmann thrombasthenia, Bernard-Soulier syndrome, storage pool disease, and secretion defects through distinctive agonist response patterns.
- Screening for von Willebrand disease using ristocetin-induced platelet agglutination as part of a broader workup including von Willebrand factor antigen and activity assays.
- Transfusion and hemostatic planning: Supporting decisions on platelet concentrate transfusion, desmopressin (DDAVP) administration, and antifibrinolytic therapy in patients with documented platelet dysfunction.
- Postoperative and research monitoring: Evaluating platelet function recovery after surgery, extracorporeal circuits, or device implantation, and supporting clinical studies of hemostatic agents.
FAQ
Q: Why is platelet aggregation testing needed when my platelet count and coagulation screen are normal?
A: Routine coagulation tests evaluate coagulation factors, and a platelet count only quantifies the number of platelets. Platelet aggregation testing assesses whether platelets function correctly. A patient can have a completely normal count and coagulation screen yet still carry significant platelet dysfunction, particularly if taking antiplatelet drugs or having an inherited function disorder.
Q: How should antiplatelet medications be managed before testing or surgery?
A: For diagnostic testing of intrinsic platelet function, aspirin and NSAIDs are typically withheld for at least 7 days and P2Y12 inhibitors for 7–14 days where clinically safe. For surgical planning, the interruption interval must balance thrombotic risk against bleeding risk and should be decided by the surgical and cardiology teams in consultation, often supported by platelet function test results.
Q: What does a reduced aggregation result mean?
A: Reduced aggregation may reflect antiplatelet medication effect, inherited platelet disorders, uremia, liver disease, myeloproliferative conditions, or preanalytical issues. Interpretation depends on which agonist responses are impaired; a characteristic pattern across the agonist panel guides the differential diagnosis and should always be correlated with clinical history.
Q: How long does the test take?
A: Once the sample reaches the laboratory, analysis of a full agonist panel by light transmission aggregometry typically takes 1–2 hours, while whole blood impedance methods can deliver results within approximately 10–15 minutes. Overall turnaround including reporting is commonly within the same working day.
Q: Are there limitations to platelet aggregation testing?
A: Yes. Results are sensitive to preanalytical variables such as sample age, temperature, transport conditions, and interfering medications. Mild platelet secretion defects may not be detected by standard aggregometry and may require supplementary testing such as dense granule ATP release assays, flow cytometric platelet surface glycoprotein analysis, or lumiaggregometry. Testing should therefore be performed in experienced, accredited laboratories with strict standardization.